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Kaposi sarcoma (KS) is the most common neoplasm in
HIV-infected subjects, and is associated with infection by
Kaposi's sarcoma-associated herpesvirus (KSHV). Our
previous studies have shown that KSHV epidemiology in
South Texas is distinct with an increased KSHV seropreva-
lence in blood donors and unique distribution of KSHV
genotypes in KS subjects. However, KSHV epidemiology
in the HIV-infected population in South Texas remains
undefined.
In this cross sectional study, we examined specific anti-
bodies to KSHV latent nuclear antigen (LANA) by immun-
ofluorescence antibody assay (IFA) and to KSHV lytic
antigen ORF65 by ELISA in 25 HIV-infected KS subjects,
314 HIV-infected subjects, and 335 HIV-negative subjects.
Relative antibody titers to ORF65 were estimated based
on optical density values (O.D.). Blood and saliva viral
loads were also determined in KSHV-seropositive subjects
by quantitative real-time PCR. Antibodies to KSHV anti-
gens were detected in 25 (100%) KS subjects, 114 (36%)
HIV-infected subjects and 65 (19%) HIV-negative sub-
jects. KS subjects had higher antibody titers to ORF65
compared to HIV-infected and -negative subjects (median
O.D. 0.76 versus 0.47 and 0.27; p = 0.0017 and 0.0001,
respectively). Antibody titers in HIV-infected subjects
were also significantly higher than HIV-negative subjects
(p = 0.0001).
Among the HIV-infected subjects, males had higher KSHV
seroprevalence than females (42%, 95% CI: 35.6–47.4%
versus 8%, 95% CI: 0.5–15.8%, p < 0.0001). Compared to
subjects with >400 CD4+ T cell counts, those with <200
CD4+ T cell counts had higher KSHV seroprevalence (OR
= 2.59, 95% CI: 1.4–4.80, p = 0.017) and higher antibody
titers (median O.D. 0.48 versus 0.32; p = 0.001). KSHV
blood and saliva viral loads were detected in 12 (48%)
and 9 (36%) of 25 KS subjects, 16 (26%) and 12 (19%) of
62 HIV-positive KSHV-seropositive subjects, and none of
the HIV-negative KSHV-seropositive subjects, respectively.
Among the KS subjects, KSHV blood and saliva viral loads
were detected more frequently in those with active KS
than those without active KS (81.8%, 95% CI: 48.2–
97.7% and 54.5%, 95% CI: 23.3–83.2% versus 18%, 95%
CI: 2.2–51.7% and 45%, 95% CI: 16.7–76.6%, p = 0.004
and 0.05, respectively). Together, these results indicate
that HIV infection and the status of HIV disease might
modulate KSHV infection and replication, and impact the
development of KS.
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